Related Experiment Video
Updated: Jul 12, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant
Jennifer L Goldstein1, Jennifer McGlaughon2, Dona Kanavy3
1Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
The Clinical Genome Resource (ClinGen) developed specific guidelines for classifying GAA gene variants in Pompe disease. This work enhances the accuracy of genetic variant interpretation, aiding diagnosis and carrier identification.
Area of Science:
- Genomics and Precision Medicine
- Clinical Genetics
- Biocuration
Background:
- Accurate clinical significance determination of genetic variants is crucial for integrating genomics into healthcare.
- The Clinical Genome Resource (ClinGen) utilizes Variant Curation Expert Panels (VCEPs) to specify gene- and disease-specific guidelines for variant classification.
- Pompe disease diagnosis, carrier identification, and newborn screening interpretation rely on accurate genetic variant classification.
Purpose of the Study:
- To specify the American College of Medical Genetics & Genomics and Association for Molecular Pathology's (ACMG/AMP) criteria for GAA variants in Pompe disease.
- To update GAA-specific variant classification guidelines and compare ClinGen Lysosomal Diseases (LD) VCEP classifications with existing ClinVar data.
- To enhance the public knowledge base on GAA variant pathogenicity and resolve classification discrepancies.
Main Methods:
- Specification of ACMG/AMP criteria tailored for GAA variants by the ClinGen LD VCEP.
- Submission of expert-curated GAA variant classifications and supporting data to public databases (ClinVar, ClinGen Evidence Repository).
- Comparative analysis of LD VCEP's GAA variant classifications against those submitted to ClinVar.
Main Results:
- The LD VCEP has submitted classifications for 243 GAA variants to public databases.
- The VCEP's efforts have increased the number of expert-curated GAA variants in ClinVar.
- This work aids in resolving conflicting classifications and addressing variants of uncertain significance.
Conclusions:
- The ClinGen LD VCEP has successfully adapted and specified ACMG/AMP criteria for GAA variants in Pompe disease.
- The curated variant data improves the reliability of genetic testing for Pompe disease diagnosis and newborn screening.
- This initiative significantly contributes to the understanding and clinical interpretation of GAA variants.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Lysosomal Hydrolases